epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.
EPI-405, Phase III. Recruiting
A rare inherited neuromuscular disorder (genetically confirmed)
TSR-405 against placebo in an inherited neuromuscular disorder. Sponsor: Tailspin Rare Diseases (fictional), Rare disease.
QTLs at a glance
Data to September 30th 2026. Each measure links to its chart below.
Quality tolerance limits (acceptable ranges, in ICH E6(R3)), most important first. Priority is how likely this study's design makes a breach, times how strongly the evidence links the measure to a reliable result. Each has an early-warning line, a limit and a critical line where the study's power would fall to the escalation level.
Rank
QTL
Likelihood
Impact
Why it is likely here
Watched at sites by
Warning
Limit
Critical
1
Missing primary endpoint dataEvidence grade A
2
3
Follow-up burden and duration (EB-17)From the design: How heavy is the visit and procedure schedule? Heavier than typical
Procedural and visit burden (visits, blood draws, questionnaires) (PD-03)From the design: How heavy is the visit and procedure schedule? Heavier than typical
Lost to follow-up or withdrew consentEvidence grade A
2
3
Follow-up burden and duration (EB-17)From the design: How heavy is the visit and procedure schedule? Heavier than typical
Procedural and visit burden (visits, blood draws, questionnaires) (PD-03)From the design: How heavy is the visit and procedure schedule? Heavier than typical
Placebo or no-added-treatment control arm (PD-05)From the design: What does the control arm receive? Placebo or no added treatment
Procedural and visit burden (visits, blood draws, questionnaires) (PD-03)From the design: How heavy is the visit and procedure schedule? Heavier than typical
Study drug at the siteTighter KRI threshold at sites in Turkey, for currency crisis with a fixed pharmaceutical exchange rate (Turkey 2018–2026). The QTL itself stays study-wide.
Too early to judge% of patients; benchmark median 7.9%
Show data
Missing primary endpoint data: running rate by month
Month
Patients
Rate
Mar 2026
1
0%
Jun 2026
3
0%
Sep 2026
4
0%
Oct 2026
5
0%
The acceptable range is the drop-out the study's power calculation allowed for (planner parameters, D24); the early-warning line sits at two-thirds of it
Lost to follow-up or withdrew consent
Too early to judge% of patients; benchmark median 3.7%
Show data
Lost to follow-up or withdrew consent: running rate by month
Month
Patients
Rate
Sep 2025
1
0%
Dec 2025
3
0%
Mar 2026
4
0%
Jun 2026
5
0%
Sep 2026
7
0%
Oct 2026
7
0%
epiClinical assumption: above the combined benchmark median of 3.7% and in line with published case studies that set limits around 4% for unknown survival status
Stopped study treatment early
Too early to judge% of patients; benchmark median 10.7%
Show data
Stopped study treatment early: running rate by month
Month
Patients
Rate
Sep 2025
1
0%
Dec 2025
3
0%
Mar 2026
4
0%
Jun 2026
5
0%
Sep 2026
7
0%
Oct 2026
7
0%
epiClinical assumption: above the Phase III benchmark of 11.5%; a breach dilutes the treatment effect and reduces power
Ineligible patients randomised
Too early to judge% of patients; benchmark median 3.2%
Show data
Ineligible patients randomised: running rate by month
Patients needed before a QTL is judged: 50. epiClinical assumption: QTL rates are unstable with few patients, and many early breaches in vendor data were noise (review note 01).
Breaches and decisions
No QTL in EPI-405 has passed its early-warning line, so nothing needs evaluating.
Critical lines assume each study was designed for 80% power at a two-sided 5% level, and mark where power would fall to 70%. Missing outcome data can bias a result well before it costs power, so its limit, not its critical line, is the one to act on.